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Abstract 
Introduction: Randomized pre-post designs, with outcomes measured at baseline and follow-ups, have 
been commonly used to compare the clinical effectiveness of two competing treatments. There are vast, 
but often conflicting, amount of information in current literature about the best analytic methods for pre-
post design. It is challenging for applied researchers to make an informed choice.  
Methods: We discuss six methods commonly used in literature: one way analysis of variance (“ANOVA”), 
analysis of covariance main effect and interaction models on post-treatment measurement (“ANCOVA I” 
and “ANCOVA II”), ANOVA on change score between baseline and post-treatment measurements, 
repeated measures (“RM”) and constrained repeated measures (“cRM”) models on baseline and post-
treatment measurements as joint outcomes. We review a number of study endpoints in pre-post designs 
and identify the difference in post-treatment measurement as the common treatment effect that all six 
methods target. We delineate the underlying differences and links between these competing methods in 
homogeneous and heterogeneous study population.  
Conclusion: We demonstrate that ANCOVA and cRM outperform other alternatives because their 
treatment effect estimators have the smallest variances. cRM has comparable performance to ANCOVA I 
main effect model in homogeneous scenario and to ANCOVA II interaction model in heterogeneous 
scenario. In spite of that, ANCOVA has several advantages over cRM, including treating baseline 
measurement as covariate because it is not an outcome by definition, the convenience of incorporating 
other baseline variables and handling complex heteroscedasticity patterns in a linear regression 
framework.    
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1. Introduction 
Two arm parallel randomized design has been widely used to compare the clinical effectiveness of 
competing treatments in improving patients’ health outcomes. In these trials, continuous outcomes of 
interest are routinely measured at baseline and one follow up time point after treatment. Common 
statistical methods used in analyzing pre-post designs include: one way analysis of variance model 
(ANOVA),1 analysis of covariance model adjusting for the baseline measurement (ANCOVA I) 2-5 and 
ANCOVA including the baseline measurement by treatment interaction (ANCOVA II) on post-treatment 
measurements2,3, ANOVA on change score from the baseline (ANOVA-Change),6,7 repeated measures 
models (RM) and constrained repeated measures models (cRM) on the baseline and post-treatment 
measurements as joint outcomes8-10. Despite of the simplicity and wide application of pre-post designs, 
which method is the best analytic approach has been a debated topic and many methodological studies 
have been performed to compare different statistical methods for past decades. However, it is challenging 
for applied researchers to evaluate this vast, but often conflicting, amount of information in current 
literature and make an informed choice. 
The primary purpose of designing a pre-post randomized study is to answer the scientific question of 
interest: is treatment A more effective than treatment B? To assess the difference in the treatment 
effectiveness between two treatments, we need to select a study endpoint and quantify a treatment effect. 
Common study endpoints include post treatment score, change score from baseline measurement to post 
treatment measurement, percent change from baseline, and rate of change from baseline. The difference 
between two arms on selected study endpoint is called treatment effect. Few studies examine the links 
between these different metrics of treatment effect. These underlying connections are critical in 
understanding the equivalence among some statistical methods that may appear to be very different at the 
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first sight2. We need to be certain about the type of treatment effect each method targets and select the one 
that yields an unbiased and the most efficient estimator of the treatment effect of our interest. 
In this study we aim to review six commonly used methods (ANOVA, ANCOVA I, ANCOVA II, 
ANOVA-Change, RM, cRM) from a practical standpoint, and we focus on delineating the differences and 
underlying connections between these methods. In section (2), we provide notations and assumptions for 
a typical pre-post design, define homogeneous and heterogeneous study population, and discuss common 
study endpoints and associated treatment effects. In section (3), we first outline these competing models 
using the same set of population mean, variance, and covariance parameters, and then assess differences 
and links between them in homogeneous and heterogeneous scenarios; In section (4), we present three 
simulated weight loss trial data examples (homogeneous data, heterogeneous data with balanced design, 
heterogeneous data with unbalanced design) to exemplify the differences and links between different 
statistical methods. In the last section, we discuss the results and give recommendation on the best 
analytical approach in pre-post designs.  
2. A hypothetical weight loss trial and metrics of treatment effect 
2.1 Notations 
In a hypothetical two arm parallel weight loss trial comparing the effect of a new drug (“treatment”) 
and a placebo (“control”) in reducing participants’ weights,  we use	"#$%  to denote weight of the &th 
patient	(& = 1,2,3, ….$) in the treatment arm  0	(0 = 0,1)  at equally spaced time point 2	(2 = 23	, 24	). .3 
and .4	are the number of subjects in the control and treatment arms.  
We denote the mean baseline weights for the treatment and control arms by	64%7  and 63%7, respectively. 
It is reasonable to assume 64%7 = 	63%7 under randomization and we let 6%7 denote the common baseline 
weight mean. Mean weights at the follow-up time point		24	in the treatment and control arms are denoted 
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by	64%8and 63%8, respectively (Figure 1). We define homogeneous and heterogeneous study populations 
as follows:  
i) The homogeneous scenario: every subject, in either the treatment or control arm, has the same 
pattern of variance and covariance structure for their baseline and follow-up weights. 
∑ = : ;3<=;3;4 =;3;4;4< >, 
where ;3< and ;4<	are the variances of weight measurements at baseline and follow-up, = is the 
correlation coefficient between the baseline and follow-up weights.  
ii) The heterogeneous scenario: variance and covariance structures of the baseline and follow-up 
weights differ between the treatment and control arms. The variance and covariance matrix for 
the control arm is 
                  ∑3 = : ;3<=3;3;34 =3;3;34;34< >, 
The variance and covariance matrix for the treatment arm is  
∑4 = : ;3<=4;3;44 =4;3;44;44< >, 
where ;3< is the common variance of weights at baseline for both control and treatment arms. 
Both arms have the same baseline variances	because of randomization at baseline.	;34<  and ;44<  
are variances of weight measurements at follow-up in the control and treatment arms. =3 and =4 are the correlation coefficients between weight measurements at baseline and follow-up in 
the control and treatment arms, respectively.  In practice, the correlation between the pre- and 
post-treatment measurements are usually stronger in the control arm than in the treatment arm. 
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Variability of post-treatment measurement tends to be larger in the treatment arm than in the 
control arm because participants may respond to the treatment more differently. i.e., =3 > =4 
and ;44< > ;34< . 
2.2 Metrics of treatment effect 
We discuss the following three commonly reported metrics of treatment effect in pre-post trials: 
i)  The primary endpoint is weight at the follow-up time point	24. The difference in mean weights 
at 24 between two arms is the treatment effect: @ = 64%8 − 63%8	
e.g, if @ = −10, we can interpret the results as “at the end of the trial, the mean weight was 10 
pounds lower in the treatment group than in the control group.” 
ii) The primary endpoint is change score calculated by subtracting the follow up weight from the 
baseline weight ∆#$= "#$%8 − "#$%7. The mean difference in change scores between two arms is 
the treatment effect. Formally, we have: @̃ = (64%8 − 64%7) − (63%8 − 63%7) 
e.g. if @̃ = −10, this difference is normally interpreted as “weight reductions were 10 pounds 
greater on treatment than control.”. Since we have  63%8 = 63%7  due to randomization, it follows 
directly @̃ = 	@. Furthermore, when we code “0” for the baseline time point (23 = 0) and “1” for 
the follow-up time point (24 = 1)	, mean change score for each arm can also be interpreted as 
mean change rate per unit time for each arm, represented by slopes in Figure (1). Thus, 
difference in slopes, denoted by @̃D = E4 − E3, is also equivalent to @.  As we will discuss in 
details in section (3), ANOVA and ANCOVA target 	@, ANOVA-CHANGE targets	@̃, and RM 
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targets @̃D	.		We can compare these seemingly very different statistical methods in a meaningful 
way because of the equivalence between	@, @̃,	and @̃D  in randomized pre-post designs.  
iii) The primary endpoint is the percent change from baseline weight, denoted by F#$ =
(GHIJ8KGHIJ7)GHIJ7 . Treatment effect is the mean difference in the percentage change between two 
arms and formally defined as follows:  @∗ = FM4 − FM3, 
where FM4	and FM3 are the mean percentage change in the treatment and control arms. Although 
percent change is popular among clinical researchers, this metric has several drawbacks11-13. 
First, percent change is a function of ratio  
GHIJ8GHIJ7 . The distribution of percent change is highly 
skewed.  Analyzing it with normal-theory based statistical methods is not justified and non-
parametric statistical methods are generally less powerful; Second, percent change is not a 
symmetric and additive measure. For example, mean weight of adults over 20 in US is 197.8 
pound for men and 170.5 pound for women. The mean difference is 27.3 pound between men 
and women. Men weight 100×((197.8-170.5)/170.5)=16% more than women, whereas women 
weight 100×((197.8-170.5)/197.8)=13.8% less than men. The percentage differences could be 
different depending on which sex is used as devisor. If a participant’s weight increases by 10% 
in first 6 months and fall by 10% for the next 6 months, the two percentage changes do not 
cancel out. The participant’s weight at the end would be only 99% of the participant’s starting 
weight.  
3. Statistical methods 
In sections (3.1) and (3.2), we focus on six methods aiming to estimate @. We describe each statistical 
model using the same set of population mean, variance, and covariance parameters defined in section (2) 
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for homogeneous and heterogeneous scenarios, separately. We present the closed-form expressions of 
each point estimator of treatment effect and its variance. It often goes unnoticed in practice that different 
statistical methods target different types of variances (i.e., conditional vs. unconditional variances) for the 
corresponding treatment effect estimators. Baseline measurement is random because we rarely can fix the 
baseline characteristics of participants when we enroll them into randomized trials. Thus, unconditional 
variance and corresponding unconditional inference is of greater interest. However, covariate adjusted 
OLS model-based variances for ANCOVA are conditional because OLS assumes adjusted covariates are 
fixed. We will discuss in details whether OLS model-based conditional inference (i.e., test statistics and 
p-values from standard statistical software) is still valid for unconditional hypothesis testing and the 
potential fixes that we can use to draw valid unconditional inference if the usual OLS model-based 
inference is biased.   
3.1 When the study population is homogeneous 
Method 1: ANOVA modeling post treatment measure (“ANOVA-Post”). We model weight at follow-
up "#$%8using the binary treatment indicator N#$  (1 if in the treatment arm; 0 if in the control arm) as 
follows: 
"#$%8 = O3(4) + O4(4)N#$ + Q#$(4), & = 1,2,… , .$; 0 = 0, 1;  (1) 
Q#$(4) ~T(0, ;4<), 
where  O3(4) = 63%8, O4(4) = 64%8 − 63%8 = @, and Q#$(4) is independently and identically distributed (i.i.d) 
random error. O4(4)	represents the treatment effect. Model (1) is homoscedastic with a constant residual 
variance  ;4<. 
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We fit an ordinary least squares (OLS) regression to estimate the coefficients and standard errors for 
model (1). The closed-form expressions of the OLS estimator OU4,VWX(4) 	 and its variance, denoted by YZ[(OU4,VWX(4) ), are presented in Table 1. OU4,VWX(4) 	is estimated by the sample group mean difference in post-
treatment weight between two arms. OU4,VWX(4) 	  is unbiased for @ . The OLS model-based variance of OU4,VWX(4) 	assuming known ;4< is expressed as follows: 
YZ[VWX(OU4,VWX(4) ) = ;4<∑ ∑ (N#$ − N..)<\I#]44$]3 	, 
where N.. = ∑ ∑ ^HI_IH`88I`7\7a\8 = \8\7a\8. ;4< is estimated by  
;b4< = ∑ ∑ cd#$%8 − db#$%8(4) e<\I#]44$]3 (.3 + .4 − 2) , 
where db#$%8(4) = OU3,VWX(4) + OU4,VWX(4) N#$	is the predicted value from fitted model (1). We let YZ[f VWX(OU4,VWX(4) ) denote 
the OLS model-based variance estimator with the estimator ;b4<, which is output by standard statistical 
software (Table 1). Since ∑ ∑ (N#$ − N..)<\I#]44$]3 = \7\8\7a\8, it follows that  YZ[VWX(OU4,VWX(4) ) = YZ[(OU4,VWX(4) ). It 
is well established that YZ[f VWX(OU4,VWX(4) ) is unbiased for YZ[VWX(OU4,VWX(4) ) in a homoscedastic linear model. Thus, YZ[f VWX(OU4,VWX(4) ) is unbiased for YZ[(OU4,VWX(4) ).  The usual OLS model-based inference (i.e., test statistics	2 =
gh8,ijk(8)lmnof ijk(gh8,ijk(8) )	 and the associated p-value) is valid for testing  pV: @ = 0 unconditionally. 
Method 2: ANCOVA modeling post treatment measure (“ANCOVA I”): We model the follow-up 
weight "#$%8using the binary treatment indicator N#$ and the baseline weight	"#$%7 .  
"#$%8 = O3(<) + O4(<)N#$ + O<(<)"#$%7 + Q#$(<) , & = 1,2, … , .$; 0 = 0, 1;  (2) 
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Q#$(<) ~T(0, ;r(s)< ) and		;r(s)< = (1 − =<);4< 
, where O3(<) = 63%8 − = t8t7 6%7 , O4(<)= @, O<(<)= = t8t7 , and  Q#$(<) is i.i.d random error. O4(<)  measures the 
treatment effect @ and O<(<)represents the slope of the pre-post association between "#$%8and "#$%7 . OLS 
assumes every subject has a common residual variance ;r(s)< .  Model (2) implicitly assumes that two arms 
share the common baseline mean 6%72. 
We fit an OLS regression to estimate the regression coefficients and standard errors for model (2). The 
OLS estimator OU4,VWX(<) 	is derived as the sample mean difference in post-treatment weight adjusting for the 
difference in sample mean baseline weight between two arms. The mean difference in baseline weight 
between two arms can be seen as chance imbalance in a randomized trial. OU4,VWX(<) 	 is unbiased for @ both 
conditional on "#$%7  and unconditionally. The formulas of OU4,VWX(<) 	 and its “unconditional” variance YZ[(OU4,VWX(<) ) are listed in Table 1. However, OLS assumes adjusted baseline weight  "#$%7  is fixed. OLS 
targets the conditional variance of OU4,VWX(<) , denoted by YZ[(OU4,VWX(<) u"#$%7v, instead of YZ[(OU4,VWX(<) ). The formula 
of YZ[(OU4,VWX(<) u"#$%7v with known common residual variance ;r(s)< 	 is presented in Table 1. Since ;r(s)<  is 
generally unknown, it is estimated by the following sample residual variance: 
;bwHI(s)< = ∑ ∑ cd#$%8 − dx&021(2) e<\I#]44$]3 (.3 + .4 − 3)  
, where 	db#$%8(<) = OU3,VWX(<) + OU4,VWX(<) N#$ + OU<,VWX(<) "#$%7	 , the predicted value from fitted model (2).  We let YZ[f VWX(OU4,VWX(<) |"#$%7)  denote the OLS model-based variance estimator with the estimator ;br(s)< . YZ[f VWX(OU4,VWX(<) |"#$%7) is output by standard statistical software (e.g. “proc reg” in SAS). Its formula is 
presented in Table 1.  
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Because we want to generalize our conclusions to study populations where values of	"#$%7 can be 
different from the values in our current sample, we may wonder whether significance tests based on the 
conditional variance assuming "#$%7 is fixed (e.g.,	2 = gh8,ijk(s)lmnof ijk(gh8,ijk(s) |GHIJ7)		) is comparable to unconditional 
inference (e.g., 2 = gh8,ijk(s)lmno(gh8,ijk(s) )), in which  "#$%7  is treated as random variable, for testing	pV: @ = 0. To 
establish this equivalence, we need to show: i) YZ[f VWX(OU4,VWX(<) |"#$%7) is unbiased for 	YZ[(OU4,VWX(<) u"#$%7v; ii) YZ[(OU4,VWX(<) |"#$%7)	is unbiased for 	YZ[(OU4,VWX(<) ). The first part is well established in a homoscedastic linear 
model. The second part holds because		YZ[(OU4,VWX(<) ) =E(YZ[(OU4,VWX(<) |"#$%7)). That is, unconditional variance 
of 	OU4,VWX(<)  is the average of its conditional variance over the distribution of baseline weight measurement. 
Therefore, the usual model-based standard errors and associated p-values are valid for unconditional 
inference2,4.  
Method 3: Repeated measures model (“RM”): Different from modeling baseline weight as a covariate 
in model (2), we model the baseline and follow up weights ("#$%7 , "#$%8) jointly using the binary treatment 
indicator N#$, the binary time factor z#$, the time by treatment interaction 	N#$ × z#$in the following RM 
model: 
"#$% = |3(}) + |4(})N#$ + |<(})z#$ + |}(})N#$ × z#$ + Q#$%(}), & = 1,2,… , .$; 0 = 0, 1; 2 = 23, 24   (3) 
~Q#$%7(})Q#$%8(}) ~T cÄ00Å , ∑e. 
When 	23 = 0  and 24 = 1 , 		|3(}) =  63%7 , |4(}) = 64%7 − 63%7,  |<(}) = 63%8 − 63%7  , and  |}(}) = (64%8 −64%7) − (63%8 − 63%7).  	|3(})represents the mean baseline weight for the control arm,  	|4(})represents the 
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difference in mean baseline weights between the treatment and control arms,  	|<(}) represents the mean 
change from the baseline weight in the control arm, and 	|}(})is generally interpreted as the difference in 
the mean change from baseline weight in a unit time interval between the treatment and control arms 
(“difference in difference”), also known as the difference in slopes. Under the randomization, we have 64%7 = 63%7  and it follows that 	|4(}) = 0	 and |}(}) = 64%8 − 64%8 = @.   Thus, testing 	pV: |}(}) = 0   is 
equivalent to testing pV:	@ = 0. 
We fit a generalized least squares (GLS) model with correlated outcomes to estimate the coefficients 
and standard errors for model (3). The closed-form expressions of  the GLS estimator of treatment effect |b},ÇWX(}) 	and its variance YZ[(|b},ÇWX(}) ) given known variance and covariance parameters are presented in Table 
1. |b},ÇWX(})  is estimated by the sample mean difference in weight change between two arms and is unbiased 
for τ asymptotically (i.e. in large sample). Variance and covariance parameters are generally unknown and 
need to be estimated using restricted maximum likelihood (REML). Conventional maximal likelihood 
estimation (MLE) should be avoided. The REML variance estimator 	YZ[f owÉW(|b},ÇWX(}) ) is derived by 
plugging the REML estimators of variance and covariance parameters (i.e., ;3<, ;4<, =;3;4 ) into the 
formula of YZ[(|b},ÇWX(}) ).We use Kenward and Roger method15 (“ddfm=kenwardroger” in SAS proc mixed 
procedure) to adjust for the potential finite sample bias in 	YZ[f owÉW(|b},ÇWX(}) ) because of its failure to 
incorporate variabilities of the REML estimators of variance and covariance parameters. This adjustment 
involves inflating variance and covariance matrix and computing an adjusted approximation degrees of 
freedom.  
Method 4: Constrained Repeated measures Model (“cRM”):  By specifying 	|4(}) in the model, RM 
model (3) assumes mean baseline weight is different between two arms. Liang and Zeger8 proposed the 
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following cRM model by fixing |4(}) = 0 to force the treatment and control arms to have the same 
intercept. Intuitively, cRM is more efficient than RM because cRM estimates one less parameter. 
Formally, we model baseline and follow-up weights ("#$%7 , "#$%8) jointly using the binary factor z#$, time 
by treatment interaction 	N#$ × z#$ in the following cRM model: 
"#$% = |3(Ñ) + |<(Ñ)z#$ + |}(Ñ)N#$ × z#$ + Q#$%(Ñ), & = 1,2, … , .$; 0 = 0, 1; 2 = 23, 24    (4) 
~Q#$%7(Ñ)Q#$%8(Ñ) ~T cÄ00Å , ∑e, 
where |3(Ñ) = 6%7 , |<(Ñ) = 63%8 − 63%7, and |}(Ñ) = @. Interpretations of |3(Ñ), |<(Ñ), and 	|}(Ñ) are the same as 
their counterparts in RM. The formulas of the GLS point estimator |b},ÇWX(Ñ)  and its variance  YZ[(|b},ÇWX(Ñ) )  are 
listed in Table 1.  |b},ÇWX(Ñ)   is unbiased for @ asymptotically. Empirical or model-based variance estimate for YZ[c|b},ÇWX(Ñ) e is derived in the same way as regular RM model using REML.  
Method 5: ANOVA with change score (“ANOVA-Change”): We model change score ∆#$= "#$%8 −"#$%7using the binary treatment indicator	N#$ as follows: 
∆#$= O3(Ö) + O4(Ö)N#$ + Q#$(Ö), & = 1,2, … , .$; 0 = 0, 1;          (5) 
                                     Q#$(Ö)~TÜ0, ;r(á)< v and 		;r(á)< = ;4< + ;3< − 2=;3;4, 
where O3(Ö) = 63%8 − 63%7 , O4(Ö) = (64%8 − 64%7) − (63%8 − 63%7) , and Q#$(})  is i.i.d random error.  O3(Ö) 
measures the mean difference score in the control arm. O4(Ö) measures the treatment effect @̃. Since 64%7 =63%7 due to randomization at baseline, O4(Ö) is reduced to @.  The closed-form expressions of OU4,VWX(Ö)  and YZ[(OU4,VWX(Ö) ) are listed in Table 1. 	Oh1,àâä(5)  is derived as the sample mean difference in weight change between 
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two arms (“difference in difference”) and is unbiased for @ . The OLS model-based variance of OU4,VWX(Ö) 	assuming known ;r(á)<  is  
YZ[VWX(OU4,VWX(Ö) ) = ;r(á)<∑ ∑ (N#$ − N..)<\I#]44$]3 	, 
where N.. = ∑ ∑ ^HI_IH`88I`7\7a\8 = \8\7a\8. ;r(á)<  is estimated by  
;br(á)< = ∑ ∑ c∆#$ − ∆å#$(Ö)e<\I#]44$]3(.3 + .4 − 2) , 
where ∆å#$(Ö)	is the fitted value from OLS model (5). We let YZ[f VWX(OU4,VWX(Ö) ) denote the OLS model-based 
variance estimator with the estimator ;br(á)< , which is output by standard statistical software (Table 1). Since ∑ ∑ (N#$ − N..)<\I#]44$]3 = \7\8\7a\8, it follows that  YZ[VWX(OU4,VWX(Ö) ) = YZ[(OU4,VWX(Ö) ). It is well established that YZ[f VWX(OU4,VWX(Ö) )  is unbiased for YZ[VWX(OU4,VWX(Ö) ) , and thus for YZ[(OU4,VWX(Ö) ) . The usual OLS model-based 
inference is valid for unconditional hypothesis testing. 
3.2 When the study population is heterogeneous 
Method 6: ANCOVA II:  Different variance and covariance structures in the treatment and control 
arms suggest a baseline measurement by treatment interaction term in ANCOVA2,3,9,10. To estimate @ 
using an interaction model, we first compute the mean centered baseline weight "ç#$%7by subtracting overall 
mean baseline weight from individual baseline weight. i.e., "ç#$%7 = "#$%7 − 6%7. We then model the post-
treatment weight "#$%8using the binary treatment indicator N#$, the mean centered baseline weight "ç#$%7 , 
and the baseline by treatment interaction N#$ × "ç#$%7   as follows:  
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"#$%8 = O3(é) + O4(é)N#$ + O<(é)"ç#$%7 + O}(é)N#$ × "ç#$%7 + Q#$(é) , & = 1,2, … , .$; 0 = 0, 1;     (6) 
Q#3(é)~T(0, 		;r7(è)< 	)  and 		;r7(è)< = (1 − =3<);34<  
Q#4(é)~T(0, 		;r8(è)< ) and 		;r8(è)< = (1 − =4<);44<  
, where	 O3(é) = 63%8 , O4(é) = 	@, O<(é) = =3 t7J7t7  , and	O}(é) = =4 t8J8t7 − =3 t7J7t7 . Q#3(é) and Q#4(é) are i.i.d random 
errors in the control and treatment arms. O4(é)is the parameter associated with the treatment effect. O<(é)is 
the regression slope of baseline weight in the control arm. O}(é)measures the difference in regression slopes 
of baseline weight between the treatment and control arms. Model (6) is heteroscedastic because error 
terms in the treatment and control arms have different residual variances.  
The OLS estimator OU4,VWX(é) 	is the adjusted mean difference in post-treatment weights controlling for a 
weighted mean difference of baseline weights between two arms with unequal weights for treatment and 
control arms (i.e., OU<,VWX(é) + OU},VWX(é) 	for the treatment group, and OU<,VWX(é)  for the control group) (Table 2). OU4,VWX(é)  
is unbiased for @ . The conditional variance of OU4,VWX(é) , denoted by 	YZ[(OU4,VWX(é) |"ç#$%7), incorporates two 
residual variances ;r7(è)<  and 		;r8(è)<  (Table 2). Standard statistical software such as SAS does not output  YZ[(OU4,VWX(é) |"ç#$%7)  because OLS assumes a common residual variance 	;r(è)< , which is the following 
weighted average of 		;r7(è)<  and 		;r8(è)< : 
	;r(è)< = \7\7a\8 		;r7(è)< + \8\7a\8 ;r8(è)< . 
We let  YZ[VWX(OU4,VWX(é) |"ç#$%7)	 denote the OLS model-based conditional variance of OU4,VWX(é)  with known 	;r(è)<  
(Table 2). Since 	;r(è)<  is generally unknown, 	;r(è)<  is estimated by 
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;br(è)< = ∑ ∑ (êHIJ8KêbHIJ8)s_IH`88I`7 (\7a\8KÑ) , 
where db#$%8 is the predicted value of d#$%8 . We let YZ[f VWX(OU4,VWX(é) |"ç#$%7)  denote the OLS model-based 
variance estimator of OU4,VWX(é)  with the estimator	;br(è)<  and known constant 6%7 (Table 2). YZ[f VWX(OU4,VWX(é) |"ç#$%7) 
is output by standard statistical software (e.g., “proc reg” in SAS). To assess the validity of model-based 
standard errors and p-values from regular ANCOVA II model for unconditional inference, we need to 
examine: i) whether YZ[f VWX(OU4,VWX(é) |"ç#$%7) is unbiased for 	YZ[(OU4,VWX(é) u"ç#$%7v; ii) whether YZ[(OU4,VWX(é) |"ç#$%7)	is 
unbiased for 	YZ[(OU4,VWX(é) ). 
First, 	YZ[f VWX(OU4,VWX(é) |"ç#$%7)  is unbiased for YZ[VWX(OU4,VWX(é) |"ç#$%7)	.  However, the unbiasedness of YZ[f VWX(OU4,VWX(é) |"ç#$%7)  as an estimator of YZ[(OU4,VWX(é) |"ç#$%7)  depends on the relationship between YZ[VWX(OU4,VWX(é) |"ç#$%7)	and YZ[(OU4,VWX(é) |"ç#$%7).  It can be shown in balanced design (.3 = .4), 
YZ[VWX(OU4,VWX(é) |"ç#$%7) 	≈ YZ[(OU4,VWX(é) |"ç#$%7). 
Thus, YZ[f VWX(OU4,VWX(é) |"ç#$%7)	is nearly unbiased for YZ[(OU4,VWX(é) u"ç#$%7v.2  When the design is unbalanced (.3 ≠.4),  
YZ[VWX(OU4,VWX(é) |"ç#$%7) 	≠ YZ[(OU4,VWX(é) |"ç#$%7) . 
Hence, YZ[f VWX(OU4,VWX(é) |"ç#$%7)  is biased for YZ[(OU4,VWX(é) |"ç#$%7) . YZ[f VWX(OU4,VWX(é) |"ç#$%7)  over-estimates YZ[(OU4,VWX(é) |"ç#$%7) if the group with larger residual variance has larger sample size and the group with 
smaller residual variance has smaller sample size, and otherwise may underestimate YZ[(OU4,VWX(é) |"ç#$%7) 2,3. 
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Second, common mean baseline weight 6%7 is generally unknown. We need to estimate 6%7in "ç#$%7using 
overall sample mean 6̂%7 = ∑ ∑ GHIJ7_IH`88I`7\7a\8   but ANCOVA treats 6̂%7 as fixed and fails to capture this 
additional variability in conditional variances. As shown below, it turns out that YZ[(OU4,VWX(é) |"ç#$%7) 
underestimates YZ[(OU4,VWX(é) ) by a factor of O},VWX[é]< YZ[Ü6̂%7v2:  
YZ[(OU4,VWX(é) ) = ñ(YZ[(OU4,VWX(é) |"ç#$%7)) + O},VWX[é]< YZ[(6̂%7). 
Thus, the OLS model-based conditional inference is biased for unconditional hypothesis testing 
because of heteroscedasticity and neglecting of sampling variability of 6̂%7. To fix these two problems, we 
can use the following adjusted heteroscedasticity-consistent (HC) variance estimator to 
replace	YZ[f VWX(OU4,VWX(é) |"ç#$%7) for valid unconditional inference: 
YZ[f nóò(OU4,VWX(é) |"ç#$%7) =YZ[f óò(OU4,VWX(é) u"ç#$%7v + OU},VWX[é]< tx7s\7a\8, 
where YZ[f óò(OU4,VWX(é) u"ç#$%7v	is a HC variance estimator for YZ[(OU4,VWX(é) |"ç#$%7)  16 and can be output from 
standard software. HC variance estimators are consistent (i.e., unbiased in large sample). Among all 
available HC variance estimators, HC2 was shown to have the best performance in finite samples2,3 (e.g. 
“HCCMETHOD=2” in proc reg, SAS). OU},VWX[é]  is the OLS estimator of O}(é), and ;b3< is the overall sample 
variance of the baseline weight measurement. It follows directly that YZ[f nóò(OU4,VWX(é) |"ç#$%7)	  is 
asymptotically unbiased for YZ[(OU4,VWX(é) )  and we can construct a valid test 2 = gh8,ijk(è)lmnof ôöõ(gh8,ijk(è) |GçHIJ7)	  for 
testing pV:	@ = 0 unconditionally. 
Method 7 ANCOVA I: We model the post-treatment weight 	"#$%8 using the binary treatment N  and 
baseline measure "#$%7: 
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"#$%8 = O3(ú) + O4(ú)N#$ + O<(ú)"#$%7 + Q#$(ú)           (7) 
Q#3(ú)~T(0, 		;r7(ù)< )  and 		;r7(ù)< = 	 (1 − =3<);34< + cO}(é)û4e<;3< 
Q#4(ú)~T(0, 		;r8(ù)< )  and 		;r8(ù)< = 	 (1 − =4<);44< + cO}(é)û3e<;3< 
,where  O3(ú) = O3(é) − O}(é)û363,  and O4(ú) = @ . Q#3(ú)	 and Q#4(ú)  are random errors in the control and 
treatment arms. Since Q#3(ú)	and Q#4(ú) have different variances in general, model (7) is heteroscedastic and 
the severity of heteroscedasticity is determined by correlation coefficient, variances of post-treatment 
measurements, and whether the design is balanced.  
The OLS estimator OU4,VWX(ú) 	is an adjusted mean difference in post-treatment weights controlling for a 
weighted mean difference of baseline measurements between two arms with equal weights for the 
treatment and control arms (i.e.,	OU<,VWX(ú)  for both arms).	OU4,VWX(ú)  is unbiased for @. Similar to ANCOVA II, 
OLS model-based inference for ANCOVA I also assumes a constant residual variance	;r(ù)< , which is a 
weighted average of 		;r7(ù)<  and 		;r8(ù)< , as follows: 
	;r(ù)< = \7\7a\8 		;r7(ù)< + \8\7a\8 ;r8(ù)< . 
Since	;r(ù)<  is unknown, it is estimated by  
;br(ù)< = ∑ ∑ (êHIJ8KêbHIJ8)s_IH`88I`7 (\7a\8K}) , 
where db#$%8 is the predicted value of d#$%8  from fitted model (7). The closed form expressions of OU4,VWX(ú) 	, the 
true conditional variance YZ[(OU4,VWX(ú) |"#$%7) with two different residual variances, the OLS model-based 
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conditional variance YZ[VWX(OU4,VWX(ú) |"#$%7)	  with known common residual variance 	;r(ù)< , and the OLS 
model-based variance estimator YZ[f VWX(OU4,VWX(ú) |"#$%7) with the estimator ;br(ù)<  are given in Table 2. Recall 
that standard statistical software reports YZ[f VWX(OU4,VWX(ú) |"#$%7). To show model-based standard errors and p-
values are valid for unconditional inference, we need to examine: i) whether YZ[f VWX(OU4,VWX(ú) |"#$%7)  is 
unbiased for 	YZ[(OU4,VWX(ú) u"#$%7v; ii) whether YZ[(OU4,VWX(ú) |"#$%7)	is unbiased for 	YZ[(OU4,VWX(ú) ). 
First,  YZ[f VWX(OU4,VWX(ú) |"#$%7)  is unbiased for YZ[VWX(OU4,VWX(ú) |"#$%7)	  but the unbiasedness of YZ[f VWX(OU4,VWX(ú) |"#$%7)  as an estimator of YZ[(OU4,VWX(ú) |"#$%7)  depends on the relationship between YZ[VWX(OU4,VWX(ú) |"#$%7)	and YZ[(OU4,VWX(ú) |"#$%7).When sample sizes are equal between two arms, we have 
	YZ[VWX(OU4,VWX(ú) |"#$%7) 	≈ YZ[(OU4,VWX(ú) |"#$%7). 
Thus,	YZ[f VWX(OU4,VWX(ú) |"#$%7) is nearly unbiased for	YZ[(OU4,VWX(ú) |"#$%7) in balanced design2. When sample sizes 
are not equal between two arms,  
YZ[VWX(OU4,VWX(ú) |"#$%7) 	≠ YZ[(OU4,VWX(ú) u"#$%7v, 
 it follows directly that YZ[f VWX(OU4,VWX(ú) |"#$%7)  is biased for YZ[(OU4,VWX(ú) |"#$%7)  due to heteroscedasticity. YZ[f VWX(OU4,VWX(ú) |"#$%7) may over-estimate YZ[(OU4,VWX(ú) |"#$%7) when the group with larger residual variance has 
larger sample size and the group with smaller residual variance has smaller sample size, and otherwise 
may underestimate YZ[(OU4,VWX(ú) |"ç#$%7) 2,3. ANCOVA I is robust against heteroscedasticity in balanced 
design, but not in unbalanced design. 
Second, different from ANCOVA II, YZ[(OU4,VWX(ú) |"#$%7)	 is unbiased for 	YZ[(OU4,VWX(ú) )  because 	YZ[(OU4,VWX(ú) ) = ñ(YZ[(OU4,VWX(ú) |"#$%7))	.  
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Thus, model-based standard errors and associated p-values are valid for unconditional inference in 
balanced design but are biased in unbalanced design. However, this bias can be easily corrected by 
replacing YZ[f VWX(OU4,VWX(ú) |"#$%7)  with an HC variance estimator YZ[f óò(OU4,VWX(ú) |"#$%7) 16 and corrected 
ANCOVA I will provide valid unconditional inference.    
Constrained Repeated Measures heterogeneous variance model (“cRM”): We model the baseline and 
follow up weights ("#$%7 , "#$%8 ) jointly using the binary time point z#$ , time by treatment interaction N#$ × z#$: 
"#$% = |3(ü) + |4(ü)z#$ + |<(ü)N#$ × z#$ + Q#$%(ü) 0 = 0, 1; & = 1,2,… .$.  (8) 
~Q#3%7(ü)Q#3%8(ü) ~T cÄ00Å ,∑3e in the control arm, 
~Q#4%7(ü)Q#4%8(ü) ~T cÄ00Å ,∑4e in the treatment arm, 
where |3(ü) = 6%7 , |<(ü) = 63%8 − 63%7, and  |<(ü) = @. Noting that subjects in the treatment and control arms 
have different variance-covariance structures for baseline and follow-up weights, we fit a cRM 
heterogeneous variance GLS model with group specific variance-covariance structure (“repeated/group=” 
in SAS proc mixed procedure specifies distinct variance-covariance structure for each treatment arm). The 
formulas of |b<,ÇWX(ü)  and YZ[c|b<,ÇWX(ü) e	are listed in Table 2. The GLS estimator |b<,ÇWX(ü) is asymptotically 
unbiased for 	|<(ü) . REML is used to derive the empirical or model-based variance 
estimator	YZ[f owÉW(|b<,ÇWX(ü) ). 
3.3 Methods comparison 
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All treatment effect estimators, except ANOVA estimator, are expressed as the mean difference in 
post-treatment measurements adjusting for the chance imbalance in baseline measurement between two 
arms in certain ways. Nonetheless, all estimators are unbiased for @ . To compare these competing 
methods, we evaluate the efficiency of point estimators of treatment effect by comparing their 
“unconditional” variances. Since the hypothesis testing of no treatment effect is based on dividing the 
point estimator by its standard error (i.e., variance divided by sample size) and rejecting the null hypothesis 
when this ratio exceeds a given threshold, the method that produces unbiased point estimate with the 
smallest unconditional variance is preferred because standard error in the dominator of statistical test 
determines the statistical power.  
3.3.1 When study population is homogeneous 
ANCOVA I is a more efficient alternative to ANOVA because YZ[(OU4,VWX(<) ) ≤ YZ[(OU4,VWX(4) ) (Table 1). 
This advantage of ANCOVA over ANOVA can also be observed from the fact that residual error variance 
of ANCOVA I is less than residual error variance of ANOVA (i.e., (1 − =<);4<  ≤ ;4< ). When the 
correlation coefficient = becomes larger, the ANCOVA I estimator has smaller variance. Since "#$%8and "#$%7are highly correlated in general,  the inclusion of  "#$%7  in  ANCOVA I explains away some variability 
in	"#$%8  and thus reduces residual variance and yields a more efficient estimator of treatment effect than 
ANOVA. 
ANOVA-Change and RM have exactly same point estimators of @ and have the same variances (Table 
1). To compare ANOVA-Change or RM with ANOVA, we can derive the difference between their 
variances as follows: 
∆= ;3(1 − 2=;4). 
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When = < 4<t8,  ∆> 0	and ANOVA outperforms ANOVA-Change and RM because ANOVA estimator 
has smaller variance. When 	= > 4<t8,	∆< 0	and ANOVA underperforms the other two methods.  
It can be shown that the difference between (“unconditional”) variances of the ANCOVA I or cRM 
estimators and those of ANOVA-Change or RM estimators are always nonnegative: 
∆	= (;4< + ;3< − 2=;3;4) − (1 − =<);4< = (;3 − =;4)< ≥ 0	
Thus, ANOVA-Change or RM is less efficient than either ANCOVA I or cRM because their estimators 
have larger variances. Intuitively ANCOVA I or cRM assumes two arms have the same mean baseline 
weights in a randomized study but ANOVA-Change or RM assumes there is a baseline difference and 
needs to estimate one extra parameter.   
As shown in Table 1, the ANCOVA I and cRM estimators of @  are equivalent because O4,VWX(<)  = £t7t8t7s .  
However, ANCOVA I plugs in the OLS estimators	OU4,VWX(<) , whereas cRM plugs in the REML estimators of 
variance and covariance parameters. The numerical difference between OU4,VWX(<)  and |b},ÇWX(Ñ)  becomes 
negligible as sample size increases. Because of this equivalence between OU4,VWX(<)  and |b},ÇWX(Ñ) ,	YZ[(OU4,VWX(<) ) and YZ[(|b},ÇWX(Ñ) ) are equal2. As discussed in section (3.1), ANCOVA I is a conditional model assuming fixed 
baseline covariates. Even though model-based variance estimates are conditional, the usual model-based 
conditional inference is still valid for unconditional hypothesis testing and ANCOVA I performs 
comparably to cRM. 
3.3.2 When study population is heterogeneous  
A heterogeneous study population justifies the inclusion of a treatment by baseline weight interaction 
term. Thus, ANCOVA II is the correctly specified model, whereas ANCOVA I is a mis-specified model. 
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In this case, the treatment effect is not assumed to be constant across different values of baseline weight, 
known as conditional treatment effect. The (“marginal”) treatment effect @  is simply the average of 
conditional treatment effect over the distribution of baseline weight and measures an overall treatment 
effect. As shown in sections (3.2), both ANCOVA models can be used to estimate @  even though 
ANCOVA I is mis-specified. Then, what is the advantage of using the more complex interaction model 
over a main effect model?  It turns out the ANCOVA II estimator OU4,VWX(é)  is more efficient than the 
ANCOVA I estimator OU4,VWX(ú)  because YZ[(OU4,VWX(é) ) 	≤ YZ[(OU4,VWX(ú) ) 3. Only when design is balanced,  YZ[(OU4,VWX(é) ) = YZ[(OU4,VWX(ú) ) and the two ANCOVA models perform comparably. Note that the OLS model-
based variance estimates for ANCOVA I and II are biased for the corresponding unconditional variances 
but HC-variance estimators provide simple fixes.  
The ANCOVA II and cRM estimators of @  are equivalent because O<(é) + O}(é) = £7t7t78t7s  and O<(é) =£8t7t88t7s  (Table 2). Two methods only differ in the way two estimators are estimated. ANCOVA II plugs in 
the OLS estimators 	OU<,VWX(é)  and OU},VWX(é) , whereas cRM plugs in the REML estimators of variance and 
covariance parameters. The numerical difference between the ANCOVA II and cRM estimators gets 
smaller as sample size increases. As discussed in section (3.2), standard statistical software such as SAS 
does not output unconditional variance for ANCOVA II directly but the usual OLS model-based standard 
errors and p-values are biased for unconditional inference in heterogeneous scenario.  Adjusted HC-
variance estimator fixes this bias. Corrected ANCOVA II provides valid unconditional inference and 
performs comparably to cRM. Another alternative approach to estimate variances of the ANCOVA I and 
II estimators is to use bootstrap method17. 
4. Numerical illustration 
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We simulated three weight loss trial data sets based on a published study for three scenarios: 
homogeneous data, heterogeneous data with balanced and unbalanced design as follows18: 
1) The baseline weights for the control and treatment arms are generated from normal distribution with 
mean 88 kg and standard deviation 14 kg. Weights at 6 month after treatment for the control arm have 
mean 86 kg and standard deviation 15 kg. This gives a ~2.3% change from baseline. Mean and standard 
deviation for weights at 6 month in the treatment arm are 83 kg and 15 kg, respectively; This corresponds 
to a 5.7% change.  
2) In homogeneous data, the correlation coefficient between baseline and follow-up weights is 0.9. 180 
subjects were assigned to the treatment and control arms equally. In heterogeneous data, the correlation 
coefficient between the baseline and follow-up weights in the control arm is 0.9 and 0.7 in the treatment 
arm. Sample sizes are (.3 = 90, .4 = 90)	for balanced design and (.3 = 60, .4 = 120)	for unbalanced 
design. We analyzed the data examples using the methods outlined in section (3).  The statistical results 
were reported in Table 3 (SAS programs are provided in the Appendix).  
In the first data example, ANOVA produced the largest standard error and the largest p-value. ANOVA-
Change and RM both outperformed ANOVA with much smaller standard errors and p-values. ANCOVA 
I and cRM outperformed ANOVA-Change and RM with smaller standard errors and p-values. Although 
ANCOVA I and cRM are equivalent when sample size is large, there are still small differences between 
the two in finite sample. 
For the second data example with a balanced design, Figure (2.a) shows that there is a strong baseline 
weight by treatment interaction. Both ANCOVA I and II have heteroscedastic errors by treatment arm 
(Figure (2.b) and (2.c)). As shown in table 2, OLS model-based standard error of ANCOVA I is very 
similar to its HC and bootstrap standard errors. Thus, heteroscedasticity does not bias model-
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standard error of ANCOVA I. Although ANCOVA II is robust against heteroscedasticity in balanced 
design, OLS model-based standard error of ANCOVA II (s.e=1.333) is still not correct because OLS fails 
to consider the variability of estimating the overall mean baseline weight. Adjusted HC standard error for 
ANCOVA II is 1.402, which is closer to model-based and HC standard errors of ANCOVA I. 
Bootstrapping standard errors for ANCOVA I and II are close to their HC or adjusted HC standard errors. 
cRM estimate and its standard error are close to those from ANCOVA I and II.  
For the third example with an unbalanced design, Figure (3.d) also reveals a baseline weight by 
treatment interaction. Both ANCOVA models have heteroscedastic errors by treatment arm (Figure (3.e) 
and (3.f)). Model-based standard errors of both ANCOVA models are not valid. Model-based standard 
errors are larger than HC standard errors and thus overestimated the true conditional variances. Compared 
with ANCOVA I, ANCOVA II has a smaller HC standard error (also smaller p-value) and thus is slightly 
more efficient. Adjusted HC standard error for ANCOVA II is very close to model-based standard error 
for cRM. Bootstrapping standard errors for ANCOVA I and II are very close to their HC or adjusted HC 
standard errors. 
5. Discussion 
In this study we compare the efficiency of six unbiased methods analyzing pre-post design.  We found 
ANCOVA and cRM are the equally most efficient methods compared with other alternatives in 
homogeneous and heterogeneous scenarios.  
The majority of previous studies only examined homogeneous study population. In this setting, 
ANOVA is one of the least efficient approaches for analyzing pre-post designs because it does not utilize 
any baseline information. ANOVA-Change and RM incorporate baseline measurement as part of 
outcome, whereas ANCOVA I adjusts baseline measurement as regression adjustment. ANCOVA I 
outperforms ANOVA-Change and RM because ANCOVA I utilizes the assumption of the balanced 
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baseline measurement between two arms in a randomized study. Thus, change score is a less efficient way 
to utilize baseline information than adjusting baseline variables as covariates. Because in randomized trials 
we seldom can control the values of baseline measurement, the assumption that baseline measurement is 
fixed required by OLS casts doubt on the validity of ANCOVA for hypothesis testing5,10. Crager proved 
ANCOVA I is valid for unconditional inference in homogeneous scenario5. This conclusion can be simply 
attributed to that the conditional variance of the ANCOVA I estimator is an unbiased estimate for its 
unconditional variance2. 
A few studies investigated further a heterogeneous scenario2,3,9,10,19. Although the heterogeneity 
justifies the inclusion of the baseline measurement by treatment interaction term, ANCOVA I and II are 
both unbiased. Yang and Tsiatis showed the ANCOVA II has smaller unconditional variance than that of 
the ANCOVA I estimator unless in balanced design20. However, the OLS model-based variances of 
ANCOVA I and II estimators, output by standard statistical software, are conditional variances, not 
unconditional variances. The OLS model-based standard errors and associated p-values for ANCOVA I 
and II are generally questionable for unconditional inference2,3,9,19, particularly when the design is 
unbalanced. With corrected HC variance estimators, both models provide valid unconditional inference. 
Choosing between ANCOVA I and II then becomes an evaluation of a trade-off between simplicity and 
some gains in efficiency.  
In homogenous setting, cRM was suggested as a superior choice to ANCOVA I because unconditional 
variance of the cRM estimator is smaller than conditional variance of the ANCOVA I estimator21. 
Kenward et al. pointed out that such direct comparison between conditional and unconditional variances 
is not meaningful. Both estimators are equivalent and cRM based on REML and Kenward-roger 
adjustment performed almost identically to ANCOVA I in finite samples15. In heterogeneous scenario, 
cRM is comparable to ANCOVA II2. In presence of missing data, applied researchers often prefer cRM 
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over ANCOVA because it can utilize all observed data but ANCOVA uses only complete cases. However, 
imputation methods which utilize the strong pre-post correlation, such as weighting and regression 
imputation, can improve the statistical power for ANCOVA without biasing estimates, making it 
comparable to cRM15.  
Furthermore, ANCOVA has several advantages over cRM: first, outcome should only be the variable 
that can be influenced by treatment.  Baseline measurement is certainly not an outcome by this definition. 
It is conceptually more appropriate to adjust baseline measurement as covariate, not model it as outcome4; 
Second, it is very convenient to include other baseline variables in a regression model for more efficient 
estimates of treatment effect. Third, it is easy to adjust for other patterns of heteroscedastic errors in an 
OLS regression. For example, we may expect larger variability in post-treatment weight associated with 
larger baseline weight. cRM cannot handle this more complex type of heteroscedasticity easily.  HC-
variance estimators for ANCOVA are simple fixes and readily implemented in statistical statistical 
software.  
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Figure 1. Hypothetical two arm pre-post weight loss randomized trial  
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Figure 2. Diagnosis plots of ANCOVA main and interaction models in heterogeneous scenario.  
a)Scatter plot of baseline and follow-up weights in balanced design. Black and red solid dots are data 
points in the treatment and control arms. Black and red solid lines are regression slopes of baseline weight 
against follow-up weight in the treatment and control arms. b) Boxplot of residuals from the treatment and 
control arms from ANCOVA I model in balanced design; c) Boxplot of residuals from the treatment and 
control arms from ANCOVA II model in balanced design; d) Scatter plot of baseline and follow-up 
weights in unbalanced design. Black and red solid dots are data points in the treatment and control arms. 
Black and red solid lines are regression slopes of baseline weight against follow-up weight in the treatment 
and control arms. e) Boxplot of residuals from the treatment and control arms from ANCOVA I model in 
unbalanced design; f) Boxplot of residuals from the treatment and control arms from ANCOVA II model 
in unbalanced design; 
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Table 1 Estimators of treatment effect and variance estimators in a homogeneous study population 
Model Estimator of Treatment Effect (!) Type*  True Variance of  Estimator OLS Model Based Variance Estimator  
ANOVA-
Post #$%,'()(%) = ,-.%/0 − ,-.2/0 U 3456#$%,'()(%) 7 = 8%9:2 + 8%9:%  345< '()(#$%,'()
(%) ) = 8=%9∑ ∑ (?@A − ?..)9BC@D%%AD2  8=%9 = ∑ ∑ 6,@A/0 − ,=@A/079BC@D%%AD2 (:2 + :% − 2)  
ANCOVA-
Post I 
#$%,'()(9)= (,-.%/0 − ,-.2/0)− #$9,'()(9) (,-.%/F − ,-.2/F) 
C 
3456#$%,'()(9) GH@A/F7 = I %BF + %B0 + 6J-.0KFLJ-.FKF7M∑ ∑ 6JNCKFLJ-.CKF7MOCNP00CPF Q 8R(M)9 , 
 8R(M)9 = (1 − T9)8%9 
345< '()(#$%,'()(9) GH@A/F7 = I %BF + %B0 +6J-.0KFLJ-.FKF7M∑ ∑ 6JNCKFLJ-.CKF7MOCNP00CPF Q 8=UNC(M)9 , 
 8=UNC(M)9 = ∑ ∑ 6,@A/0 − ,=@A/079BC@D%%AD2 (:2 + :% − 4)  
U 	3456#$%,'()(9) 7 = X 1:2 + 1:%Y (1 − T9)8%9  
RM 
Z=[,\()([)= (,-.%/0 − ,-.%/F)− (,-.2/0 − ,-.2/F) U 345(Z=[,\()([) ) = ( 1:2 + 1:%)(8%9 + 829 − 2T828%)  
cRM 
Z=[,\()(])= (,-.%/0 − ,-.2/0)− T828%829 (,-.%/F − ,-.2/F) U 3456Z=[,\()(]) 7 = X
1:2 + 1:%Y (1 − T9)8%9  
ANOVA-
Change 
#$%,'()(^)= (,-.%/0 − ,-.%/F)− (,-.2/0 − ,-.2/F) U 	345(#$%,'()(^) ) = ( 1:2 + 1:%)(8%9 + 829 − 2T828%) 
345< '()(#$%,'()(^) ) = 8=R(_)9∑ ∑ (?@A − ?..)9BC@D%%AD2 	, 
8=R(_)9 = ∑ ∑ 6∆@A − ∆a@A(^)79BC@D%%AD2(:2 + :% − 2)  
 
*  U- unconditional variance; C- conditional variance 
 
 
34 
 
 
Table 2: Estimators of treatment effect and variance estimators in a heterogeneous study population 
Model Estimator of Treatment Effect (τ) Type True Variance of  Estimator Variance Estimator from OLS Model 
ANCOVA-
Post II 
#$%,'()(b)= (,-.%/0 − (#$9,'()(b)+ #$[,'()(b) ),c-.%/F) − (,-.2/F− #$9,'()(b) ,c-.2/F) C 
3456#$%,'()(b) GHd@A/F7 = e 1:2 + ,c-.'/F9∑ 6,c@2/F − ,c-.2/F79BF@D% f 	8RF(g)9+ e 1:% + ,c-.%/F9∑ 6,c@%/F − ,c-.%/F79BF@D% f 	8R0(g)9  
 
 		8RF(g)9 = (1 − T29)82%9 , 		8R0(g)9 = (1 − T%9)8%%9  
345< '()6#$%,'()(b) GHd@A/F7= e 1:2 + 1:% + ,c-.'/F9∑ 6,c@2/F − ,c-.2/F79BF@D%+ ,c-.%/F9∑ 6,c@%/F − ,c-.%/F79BF@D% f8=R(g)9  
 8=R(g)9 = ∑ ∑ (,@A/0 − ,=@A/0)9BC@D%%AD2 (:2 + :% − 5)  
  U 
3456#$%,'()(b) 7 = 1:2 (1 − T29)82%9 +	 1:% (1 − T%9)8%%9+ XT% 8%%82 − T2 82%82 Y9 829:2 + :%  
ANCOVA-
Post I 
#$%,'()(i)= (,-.%/0 − ,-.2/0)− #$9,'()(i) (,-.%/F − ,-.2/F) C 
3456#$%,'()(i) GH@A/F7 = e 1:2 + ∑ 6,@%/F − ,-.2/F79(,-.%/F − ,-.2/F)BF@D%∑ ∑ 6,@A/F − ,-.A/F79BC@D%%AD2 f 		8RF(j)9+ e 1:%+ ∑ 6,@%/F − ,-.%/F79(,-.%/F − ,-.2/F)B0@D%∑ ∑ 6,@%/F − ,c-.%/F79BC@D%%AD2 f 		8R0(j)9  
 		8RF(j)9 = (1 − T29)82%9 , 		8R0(j)9 = (1 − T%9)8%%9  
345< '()6#$%,'()(i) GH@A/F7= e 1:2 + 1:% + ∑ 6,@%/F − ,-.2/F79(,-.%/F − ,-.2/F)BF@D%∑ ∑ 6,@A/F − ,-.A/F79BC@D%%AD2+ ∑ 6,@%/F − ,-.%/F79(,-.%/F − ,-.2/F)B0@D%∑ ∑ 6,@%/F − ,c-.%/F79BC@D%%AD2 f8=k(7)9  
 8=k(7)9 = ∑ ∑ (,@A/0 − ,=@A/0)9BC@D%%AD2 (:2 + :% − 4)  
  U 
3456#$%,'()(i) 7 = 	 %BF [(1 − T29)82%9 + ((T% n00nF − T2 nF0nF )o%)9829 +%B0 [(1 − T%9)	8%%9 + ((T% n00nF − T2 nF0nF )o2)9829]  
cRM 
Z=[,\()(]) = (,-.%/0 − ,-.2/0) −(pFnFnF0nFM (,-.%/F − ,-../F) −p0nFn00nFM (,-.%/F − ,-../F)) U 
3456Z=[,\()(]) 7 = 	 %BF [(1 − T29)82%9 + ((T% n00nF − T2 nF0nF )o%)9829 +%B0 [(1 − T%9)	8%%9 + ((T% n00nF − T2 nF0nF )o2)9829]  
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Table 3- Statistical analysis of the three simulated data examples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 OLS regression model-based standard error 
2 HC standard error for ANCOVA I (main effect) model  
3 Modified HC standard error for ANCOVA II (interaction) model 
4 Bootstrapping standard error (n=5000) 
 
Scenario Method Estimate 
Standard 
error 
p-value 
Homogeneous 
ANOVA -3.089 2.106 0.144 
ANCOVA I -2.422 0.955 0.0121 
ANOVA-Change -2.354 0.971 0.0163 
RM -2.354 0.971 0.0163 
cRM -2.434 0.944 0.0108 
Heterogeneous  
( =90, ) 
ANCOVA I -3.203 
1.4031  0.0235 
1.3972 0.0231 
1.4004 n/a 
ANCOVA II -3.165 
1.3331 0.0187 
1.4023 0.0252 
1.3974 n/a 
cRM -3.203 1.405 0.0241 
Heterogeneous (
=60, ) 
ANCOVA I -3.416 
1.4151 0.0167 
1.2792 0.0083 
1.2814 n/a 
ANCOVA II -3.399 
1.3761 0.0145 
1.2583 0.0076 
1.2604 n/a 
cRM -3.396 1.262 0.0078 
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Appendix 
 
SAS programs for ANCOVA I, ANCOVA II, and cRM in a heterogeneous scenario 
 
*****compute overall mean of baseline measurement****; 
proc means data=data3 mean std stderr; 
     var y0 ; 
     output out=meandata mean=y0bar stderr=y0err; 
    run; 
 
***create mean centered baseline variable y0cen***; 
data data3_1; 
     set data3; 
     y0cen=y0-90.0817872; 
     int_y0cen=trt*y0cen; 
    run; 
 
***ANCOVA I including main effect of treament and baseline variable y0***; 
***use HHMETHOD=2 to compute HC2 variance***; 
proc reg data=data3_1; 
         model y1=trt y0/white HCCMETHOD=2; 
        run; 
 
***ANCOVA II including treatment, y0cen, and the interaction term***; 
***use HHMETHOD=2 to compute HC2 variance***; 
proc reg data=data3_1; 
     ods output ParameterEstimates=perobust; 
     model y1=trt y0cen int_y0cen/white HCCMETHOD=2; 
    run; 
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data perobust2; 
     set perobust; 
     keep variable estimate stderr tvalue probt hcstderr; 
    run; 
 
proc sql noprint; 
     select y0bar into: y0bar 
  from meandata; 
     select y0err into: y0err 
  from meandata; 
 
%put &y0bar &y0err; 
 
proc sql noprint; 
     select estimate into: beta0 
  from perobust2 
  where variable="Intercept"; 
     select estimate into: beta1 
  from perobust2 
  where variable="trt"; 
     select estimate into: beta2 
  from perobust2 
  where variable="y0cen"; 
     select estimate into: beta3 
  from perobust2 
  where variable="int_y0cen"; 
 
data perobust3; 
     set perobust2; 
 * if variable="Intercept" then modified_hcstderr=sqrt(hcstderr**2+((&beta2)**2)*((&y0err)**2)); 
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  if variable="trt"       then modified_hcstderr=sqrt(hcstderr**2+((&beta3)**2)*((&y0err)**2)); 
 * if variable="y0cen"     then modified_hcstderr=hcstderr; 
 * if variable="int_y0cen" then modified_hcstderr=hcstderr; 
  corrZ=estimate/modified_hcstderr; 
  pvalue=2*(1-probnorm(abs(corrZ))); 
  if variable in ("Intercept","trt")   then pvalue2=2*(1-probt(abs(corrz),176)); 
  *if variable in ("y0cen","int_y0cen") then pvalue2=2*(1-probt(abs(corrz),299)); 
  if  variable="trt" ; 
  keep variable estimate stderr tvalue probt hcstderr modified_hcstderr corrz pvalue pvalue2; 
  run; 
 
data mixeddata3; 
     set data3; 
     do; y=y1;time=1;time2=time;output;end; 
     do; y=y0;time=0;time2=time;output;end; 
     run; 
 
title "constrained repeated measures (cRM) with heterogeneous variance"; 
***analysis 6- conditional longitudinal analysis (fix arm term to be 0)***; 
proc mixed data=mixeddata3 method=reml order=data cl=wald; 
     class time subj; 
     model y=time2 trt*time2/ddfm=kenwardroger solution alpha=0.05; 
     repeated time/subject=subj type=un group=trt rcorr; 
     run; 
 
